Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report)'s share price was up 8.6% during trading on Monday . The stock traded as high as $5.92 and last traded at $5.71. Approximately 181,960 shares were traded during trading, an increase of 153% from the average daily volume of 71,929 shares. The stock had previously closed at $5.26.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on COYA. D. Boral Capital reaffirmed a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Tuesday. Chardan Capital reiterated a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, March 20th.
Get Our Latest Report on COYA
Coya Therapeutics Stock Performance
The firm has a 50 day moving average price of $6.17 and a two-hundred day moving average price of $6.41. The company has a market cap of $103.36 million, a P/E ratio of -9.51 and a beta of 0.49.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million. On average, sell-side analysts predict that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.
Hedge Funds Weigh In On Coya Therapeutics
Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics during the fourth quarter valued at about $59,000. Jane Street Group LLC bought a new position in shares of Coya Therapeutics in the fourth quarter valued at approximately $74,000. Northern Trust Corp grew its stake in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after acquiring an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in Coya Therapeutics during the 4th quarter worth approximately $401,000. 39.75% of the stock is owned by institutional investors.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Articles
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
